Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KVUE Stock Forecast 2025-2026
$23.20
Current Price
$45.43B
Market Cap
Buy 4
Hold 14
Sell 0
Wall St Analyst Ratings
Distance to KVUE Price Targets
+25.0%
To High Target of $29.00
+5.6%
To Median Target of $24.50
-5.2%
To Low Target of $22.00
KVUE Price Momentum
-3.6%
1 Week Change
+1.3%
1 Month Change
+13.0%
1 Year Change
+8.7%
Year-to-Date Change
-7.8%
From 52W High of $25.17
+31.3%
From 52W Low of $17.67
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Kenvue (KVUE) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on KVUE and similar high-potential opportunities.
Latest KVUE Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, KVUE has a neutral consensus with a median price target of $24.50 (ranging from $22.00 to $29.00). The overall analyst rating is Buy (6.8/10). Currently trading at $23.20, the median forecast implies a 5.6% upside. This outlook is supported by 4 Buy, 14 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Susan Anderson at Canaccord Genuity, projecting a 25.0% upside. Conversely, the most conservative target is provided by Filippo Falorni at Citigroup, suggesting a 5.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KVUE Analyst Ratings
4
Buy
14
Hold
0
Sell
KVUE Price Target Range
Low
$22.00
Average
$24.50
High
$29.00
Current: $23.20
Latest KVUE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KVUE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 12, 2025 | Barclays | Lauren Lieberman | Equal-Weight | Maintains | $23.00 |
| May 9, 2025 | UBS | Peter Grom | Neutral | Maintains | $25.00 |
| May 9, 2025 | Citigroup | Filippo Falorni | Neutral | Maintains | $24.50 |
| Apr 14, 2025 | Citigroup | Filippo Falorni | Neutral | Maintains | $22.00 |
| Apr 14, 2025 | Barclays | Lauren Lieberman | Equal-Weight | Maintains | $22.00 |
| Apr 10, 2025 | Redburn Atlantic | Edward Lewis | Neutral | Initiates | $23.50 |
| Mar 27, 2025 | Barclays | Lauren Lieberman | Equal-Weight | Maintains | $23.00 |
| Mar 24, 2025 | Evercore ISI Group | Javier Escalante | In-Line | Initiates | $25.00 |
| Mar 5, 2025 | Canaccord Genuity | Susan Anderson | Buy | Maintains | $29.00 |
| Feb 24, 2025 | Piper Sandler | Korinne Wolfmeyer | Overweight | Maintains | $27.00 |
| Feb 7, 2025 | Canaccord Genuity | Susan Anderson | Buy | Maintains | $24.00 |
| Feb 7, 2025 | UBS | Peter Grom | Neutral | Maintains | $21.00 |
| Feb 3, 2025 | RBC Capital | Nik Modi | Sector Perform | Reiterates | $24.00 |
| Jan 17, 2025 | Barclays | Lauren Lieberman | Equal-Weight | Maintains | $21.00 |
| Jan 16, 2025 | UBS | Peter Grom | Neutral | Maintains | $23.00 |
| Jan 15, 2025 | Citigroup | Filippo Falorni | Neutral | Maintains | $21.00 |
| Jan 6, 2025 | Piper Sandler | Overweight | Upgrade | $0.00 | |
| Dec 12, 2024 | Deutsche Bank | Steve Powers | Hold | Downgrade | $24.00 |
| Oct 22, 2024 | B of A Securities | Anna Lizzul | Buy | Maintains | $27.00 |
| Oct 11, 2024 | JP Morgan | Andrea Teixeira | Overweight | Maintains | $25.00 |
Kenvue Inc. (KVUE) Competitors
The following stocks are similar to Kenvue based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Kenvue Inc. (KVUE) Financial Data
Kenvue Inc. has a market capitalization of $45.43B with a P/E ratio of 42.3x. The company generates $15.30B in trailing twelve-month revenue with a 6.9% profit margin.
Revenue growth is -3.9% quarter-over-quarter, while maintaining an operating margin of +16.7% and return on equity of +10.2%.
Valuation Metrics
Market Cap
$45.43B
Enterprise Value
$53.22B
P/E Ratio
42.3x
PEG Ratio
19.4x
Price/Sales
3.0x
Growth & Margins
Revenue Growth (YoY)
-3.9%
Gross Margin
+58.0%
Operating Margin
+16.7%
Net Margin
+6.9%
EPS Growth
+8.8%
Financial Health
Cash/Price Ratio
+2.4%
Current Ratio
0.9x
Debt/Equity
88.0x
ROE
+10.2%
ROA
+6.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Kenvue Inc. (KVUE) Business Model
About Kenvue Inc.
What They Do
Consumer healthcare and pharmaceutical company.
Business Model
The company generates revenue by offering a diverse range of health-centric products, including both prescription and over-the-counter medications. It collaborates with healthcare providers to improve product accessibility and effectiveness, targeting the health and wellness needs of individuals.
Additional Information
Kenvue Inc. boasts a broad portfolio of trusted brands and formulations, significantly impacting community health standards. The company's operations span both domestic and international markets, reinforcing its role as a key player in the consumer health sector.
Company Information
Sector
Consumer Defensive
Industry
Household & Personal Products
Employees
22,000
CEO
Mr. Thibaut Mongon
Country
United States
IPO Year
2023
Website
www.kenvue.comKenvue Inc. (KVUE) Latest News & Analysis
Latest News
Quick Summary
Kenvue surpassed Q1 profit and revenue expectations, driven by strong sales in self-care products like Tylenol and Benadryl, despite a decline in skin health and beauty product demand.
Why It Matters
Kenvue's better-than-expected earnings reflect strong demand for key products, indicating resilience amid shifting consumer preferences, which can boost investor confidence and stock performance.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
Kenvue (KVUE) shares increased in premarket trading following first-quarter results that exceeded analysts' expectations.
Why It Matters
Kenvue's stronger-than-expected first-quarter results indicate robust demand and operational efficiency, potentially boosting investor confidence and driving share price growth.
Source: Investopedia
Market Sentiment:
Positive
Quick Summary
Kenvue Inc (NYSE:KVUE) reported Q2 net sales of $3.74 billion, surpassing expectations of $3.68 billion, but down 3.9% year-over-year.
Why It Matters
Kenvue's Q2 performance shows resilience with sales exceeding forecasts, but the year-over-year decline may raise concerns about growth sustainability, impacting investor sentiment.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Kenvue, Inc. (NYSE: KVUE) will hold its Q1 2025 earnings conference call on May 8, 2025, at 8:00 AM ET, featuring key executives and major financial analysts.
Why It Matters
Kenvue's Q1 2025 earnings call will provide key insights into its financial health and strategic direction, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Kenvue Inc. (NYSE: KVUE) has appointed Amit Banati as CFO, effective May 12, 2025, succeeding Paul Ruh, who will assist during the transition. Banati will oversee Finance and Strategy functions.
Why It Matters
Leadership changes can impact a company's strategy and performance. Banati's experience in finance may influence Kenvue's growth trajectory and shareholder value, affecting investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Kenvue Reports First Quarter 2025 Results
7 days ago
Quick Summary
Kenvue Inc. (NYSE: KVUE) reported a 3.9% decrease in net sales for Q1 ended March 30, 2025, while emphasizing commitment to brand activation and sustainable growth.
Why It Matters
Kenvue's 3.9% decline in net sales signals potential challenges in revenue growth and market positioning, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About KVUE Stock
What is Kenvue Inc.'s (KVUE) stock forecast for 2025?
Based on our analysis of 20 Wall Street analysts, Kenvue Inc. (KVUE) has a median price target of $24.50. The highest price target is $29.00 and the lowest is $22.00.
Is KVUE stock a good investment in 2025?
According to current analyst ratings, KVUE has 4 Buy ratings, 14 Hold ratings, and 0 Sell ratings. The stock is currently trading at $23.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KVUE stock?
Wall Street analysts predict KVUE stock could reach $24.50 in the next 12 months. This represents a 5.6% increase from the current price of $23.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Kenvue Inc.'s business model?
The company generates revenue by offering a diverse range of health-centric products, including both prescription and over-the-counter medications. It collaborates with healthcare providers to improve product accessibility and effectiveness, targeting the health and wellness needs of individuals.
What is the highest forecasted price for KVUE Kenvue Inc.?
The highest price target for KVUE is $29.00 from Susan Anderson at Canaccord Genuity, which represents a 25.0% increase from the current price of $23.20.
What is the lowest forecasted price for KVUE Kenvue Inc.?
The lowest price target for KVUE is $22.00 from Filippo Falorni at Citigroup, which represents a -5.2% decrease from the current price of $23.20.
What is the overall KVUE consensus from analysts for Kenvue Inc.?
The overall analyst consensus for KVUE is neutral. Out of 20 Wall Street analysts, 4 rate it as Buy, 14 as Hold, and 0 as Sell, with a median price target of $24.50.
How accurate are KVUE stock price projections?
Stock price projections, including those for Kenvue Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 15, 2025 11:20 AM UTC